51116-00-8
基本信息
DBCGMP NA
DIBUTYRYL-CGMP
Bt2cGMP sodium
DIBUTYRYL-CGMP NA
DB-CGMP SODIUM SALT
Dibutyryl-cGMP sodium
N2,2'-O-Dibutyryl cGMP
DIBUTYRYL-CGMP SODIUM SALT
MGBPJXVWDGGLKI-GBIKJYCISA-M
物理化学性质
| 储存条件 | −20°C |
| 溶解度 | H2O: 50 mg/mL |
| 形态 | powder |
| 颜色 | off-white |
常见问题列表
cGMP-dependent protein kinase (PKG);
ATP-sensitive K
+
channels
Dibutyryl-cGMP is able to induce process elongation and branching in astrocytes resulting from a rapid, reversible and concentration-dependent redistribution of glial fibrillary acidic protein (GFAP) and actin filaments without significant change in protein levels.
When cells are co-incubated with Dibutyryl-cGMP (100 μM) stress fibre formation is prevented and cells acquired a stellate morphology in cerebellar astrocytes.
In cells treated with Dibutyryl-cGMP (100 μM, 2 h) the particulate fraction is nearly devoid of RhoA protein. Dibutyryl-cGMP prevents RhoA-membrane association.
Using the scratchwound model, the size of the wound is significantly smaller in cells treated with Dibutyryl-cGMP after the wound indicating that dbcGMP accelerates wound closure.
Dibutyryl-cGMP (50-200 μg/paw; subcutaneous injection; male Wistar rats) treatment antagonizes the hyperalgesic effect of PGE2 in a dose-dependent manner. Maximal antinociceptive effect of DbcGMP is at 1 h after administration and last for plus 2 h.
| Animal Model: | Male Wistar rats (180- 250 g) injection with Prostaglandin E2 (PGE2) |
| Dosage: | 50 μg/paw, 75 μg/paw, 100 μg/paw and 200 μg/paw |
| Administration: | Subcutaneous injection |
| Result: | Antagonized the hyperalgesic effect of PGE2 (2 μg/paw), in a dose-dependent manner. |